Search Results - "Vizeli, Patrick"

Refine Results
  1. 1

    Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects by Holze, Friederike, Vizeli, Patrick, Ley, Laura, Müller, Felix, Dolder, Patrick, Stocker, Melanie, Duthaler, Urs, Varghese, Nimmy, Eckert, Anne, Borgwardt, Stefan, Liechti, Matthias E

    Published in Neuropsychopharmacology (New York, N.Y.) (01-02-2021)
    “…Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy. However, no modern studies have evaluated…”
    Get full text
    Journal Article
  2. 2

    Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects by Holze, Friederike, Vizeli, Patrick, Müller, Felix, Ley, Laura, Duerig, Raoul, Varghese, Nimmy, Eckert, Anne, Borgwardt, Stefan, Liechti, Matthias E

    Published in Neuropsychopharmacology (New York, N.Y.) (01-02-2020)
    “…Lysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) is an empathogen, and D-amphetamine is a classic stimulant…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis by Vizeli, Patrick, Straumann, Isabelle, Holze, Friederike, Schmid, Yasmin, Dolder, Patrick C., Liechti, Matthias E.

    Published in Scientific reports (25-05-2021)
    “…Lysergic acid diethylamide (LSD) is a classic psychedelic substance that is used recreationally and investigated in psychiatric research. There are no…”
    Get full text
    Journal Article
  5. 5

    Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies by Studerus, Erich, Vizeli, Patrick, Harder, Samuel, Ley, Laura, Liechti, Matthias E

    Published in Journal of psychopharmacology (Oxford) (01-05-2021)
    “…Background: 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) is used both recreationally and therapeutically. Little is known about the factors influencing…”
    Get full text
    Journal Article
  6. 6

    Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects by Vizeli, Patrick, Liechti, Matthias E

    Published in PloS one (18-06-2018)
    “…Methylenedioxymethamphetamine (MDMA) increases oxytocin, empathy, and prosociality. Oxytocin plays a critical role in emotion processing and social behavior…”
    Get full text
    Journal Article
  7. 7

    MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens by Müller, Felix, Holze, Friederike, Dolder, Patrick, Ley, Laura, Vizeli, Patrick, Soltermann, Alain, Liechti, Matthias E, Borgwardt, Stefan

    Published in Neuropsychopharmacology (New York, N.Y.) (01-02-2021)
    “…It has been reported that serotonergic hallucinogens like lysergic acid diethylamide (LSD) induce decreases in functional connectivity within various…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects by Vizeli, Patrick, Straumann, Isabelle, Duthaler, Urs, Varghese, Nimmy, Eckert, Anne, Paulus, Martin P, Risbrough, Victoria, Liechti, Matthias E

    Published in Frontiers in pharmacology (13-07-2022)
    “…3,4-Methylenedioxymethamphetamine (MDMA) has shown initial promise as an adjunct in psychotherapy to treat posttraumatic stress disorder (PTSD). Its efficacy…”
    Get full text
    Journal Article
  10. 10

    No Influence of Dopamine System Gene Variations on Acute Effects of MDMA by Vizeli, Patrick, Liechti, Matthias E.

    Published in Frontiers in psychiatry (24-10-2019)
    “…3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a recreational substance also investigated as medication for posttraumatic stress disorder. Dopamine (DA)…”
    Get full text
    Journal Article
  11. 11

    Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants by Vizeli, Patrick, Studerus, Erich, Holze, Friederike, Schmid, Yasmin, Dolder, Patrick C., Ley, Laura, Straumann, Isabelle, Becker, Anna M., Müller, Felix, Arikci, Denis, Liechti, Matthias E.

    Published in Translational psychiatry (04-09-2024)
    “…The pharmacodynamic effects of lysergic acid diethylamide (LSD) are diverse and different in different individuals. Effects of other psychoactive substances…”
    Get full text
    Journal Article
  12. 12

    Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects by Dolder, Patrick C, Strajhar, Petra, Vizeli, Patrick, Hammann, Felix, Odermatt, Alex, Liechti, Matthias E

    Published in Frontiers in pharmacology (07-09-2017)
    “…Lisdexamfetamine is a prodrug of D-amphetamine used for the treatment of attention-deficit/hyperactivity disorder (ADHD). Lisdexamfetamine is thought to have a…”
    Get full text
    Journal Article
  13. 13

    In vitro and in vivo metabolism of psilocybin's active metabolite psilocin by Thomann, Jan, Kolaczynska, Karolina E, Stoeckmann, Oliver V, Rudin, Deborah, Vizeli, Patrick, Hoener, Marius C, Pryce, Christopher R, Vollenweider, Franz X, Liechti, Matthias E, Duthaler, Urs

    Published in Frontiers in pharmacology (29-04-2024)
    “…, psilocybin is rapidly dephosphorylated to psilocin which induces psychedelic effects by interacting with the 5-HT receptor. Psilocin primarily undergoes…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Safety pharmacology of acute MDMA administration in healthy subjects by Vizeli, Patrick, Liechti, Matthias E

    Published in Journal of psychopharmacology (Oxford) (01-05-2017)
    “…3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is being investigated in MDMA-assisted psychotherapy. The present study characterized the safety pharmacology…”
    Get full text
    Journal Article
  16. 16

    Safety pharmacology of acute LSD administration in healthy subjects by Holze, Friederike, Caluori, Toya V., Vizeli, Patrick, Liechti, Matthias E.

    Published in Psychopharmacology (01-06-2022)
    “…Rationale Lysergic acid diethylamide (LSD) is used in psychiatric and psychological research and investigated as a potential treatment for medical and…”
    Get full text
    Journal Article
  17. 17

    Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects by Holze, Friederike, Duthaler, Urs, Vizeli, Patrick, Müller, Felix, Borgwardt, Stefan, Liechti, Matthias E.

    Published in British journal of clinical pharmacology (01-07-2019)
    “…Aims The aim of the present study was to characterize the pharmacokinetics and exposure–subjective response relationship of a novel oral solution of lysergic…”
    Get full text
    Journal Article
  18. 18

    Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants by Müller, Felix, Kraus, Elias, Holze, Friederike, Becker, Anna, Ley, Laura, Schmid, Yasmin, Vizeli, Patrick, Liechti, Matthias E., Borgwardt, Stefan

    Published in Psychopharmacology (01-06-2022)
    “…Background LSD and psilocybin are increasingly used in phase I trials and evaluated as therapeutic agents for mental disorders. The phenomenon of reoccurring…”
    Get full text
    Journal Article
  19. 19

    MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy by Sarmanlu, Mesud, Kuypers, Kim P.C., Vizeli, Patrick, Kvamme, Timo L.

    “…The application of MDMA in conjunction with psychotherapy has in recent years seen a resurgence of clinical, scientific, and public interest in the treatment…”
    Get full text
    Journal Article
  20. 20

    The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity by Bedford, Peter, Hauke, Daniel J, Wang, Zheng, Roth, Volker, Nagy-Huber, Monika, Holze, Friederike, Ley, Laura, Vizeli, Patrick, Liechti, Matthias E, Borgwardt, Stefan, Müller, Felix, Diaconescu, Andreea O

    Published in Neuropsychopharmacology (New York, N.Y.) (01-07-2023)
    “…Psychedelics have emerged as promising candidate treatments for various psychiatric conditions, and given their clinical potential, there is a need to identify…”
    Get full text
    Journal Article